Reactive oxygen species

Where the papers sit

52 papers from the last 6 months study reactive oxygen species directly · updated from PubMed 12 Oct 2026

• Redox Injury and Repair

  Redox injury is being addressed through ferroptosis control, antioxidant nanomedicine, and metabolic remodeling. Liver studies link NOX4/ROS/NLRP3 signaling, HIF1α-KLF4, and sorafenib resistance to disease progression. ROS-scavenging hydrogels, exosomes, liposomes, and nanozymes target kidney, brain, nerve, and fibrotic injury. The work is moving toward tissue-selective control of oxidative damage rather than nonspecific antioxidant treatment.

  16 papers · 30.8%

• Nanoparticle Cancer Phototherapy

  Cancer nanomedicine is moving toward activatable photodynamic, sonodynamic, and X-ray therapies that generate or regulate ROS inside tumors. Oxygen vacancies, afterglow imaging, and organelle-targeted photosensitizers are used to improve treatment in hypoxic or deep lesions. ROS-responsive paclitaxel, curcumin, and cinnamaldehyde systems add redox disruption and controlled drug release. The recurring goal is multimodal, tumor-localized therapy with improved accumulation and imaging guidance.

  11 papers · 21.2%

• Diabetic Wound Infection

  Diabetic wound treatment is shifting toward platforms that combine biofilm killing with inflammatory and oxidative-stress control. Responsive hydrogels, nanogels, microneedles, scaffolds, and carbon dots deliver antibacterial agents, siRNA, or photodynamic therapy. Macrophage manipulation and stage-specific release recur as ways to coordinate infection clearance with tissue repair. The main open question is how these multifunctional systems perform across the changing microenvironments of chronic wounds.

  11 papers · 21.2%

• Antioxidant Therapy for Oxidative Stress

  Oxidative-stress research is favoring targeted nanozymes and redox-active materials that scavenge ROS while modifying disease pathways. Cerium, manganese, and carbon-based platforms are being tested in Alzheimer’s disease, encephalitis, diabetes, and osteoporosis, with metal chelation and mitophagy among the recurring mechanisms. NRF2 activation offers a complementary small-molecule strategy, whereas low ROS can also support gemcitabine resistance through mitophagy. The set remains exploratory, spanning protection from oxidative injury and selective restoration of redox balance.

  9 papers · 17.3%

• Oral Cancer and Ulcer Therapy

  ROS-modulating biomaterials are being applied to both oral cancer treatment and oral-ulcer repair. Santamarine enhances cisplatin through the ROS/JNK axis, caspase-3 activation, and DNA damage, while nanogels and AIEE aggregates target mitochondria or lysosomes to induce apoptosis and pyroptosis. Ulcer systems instead emphasize sustained delivery, antioxidant protection, and antibacterial sealing. The cluster therefore combines tumor cell killing with mucosal repair rather than showing one unified therapeutic direction.

  5 papers · 9.6%